Research in Clinical Dermatology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +441518081136

Editorial - Research in Clinical Dermatology (2024) Volume 7, Issue 6

Systemic Treatments for Skin Conditions: Benefits and Risks of Internal Therapies

Jane Goldust *

Dermatology Department, The University of Queensland, Australia

*Corresponding Author:
Jane Goldust
Dermatology Department, The University of Queensland, Australia
E-mail: goldust@yahoo.es

Received: 2-Nov-2024, Manuscript No. aarcd-24-151259; Editor assigned: 4-Nov-2024, PreQC No. aarcd-24-151259 (PQ) Reviewed:18-Nov-2024, QC No. aarcd-24-151259Revised:25-Nov-2024, Manuscript No. aarcd-24-151259; Published:30-Nov-2024, DOI: 10.35841/aarcd- 7.6.239

Citation: Goldust J. Systemic treatments for skin conditions: Benefits and risks of internal therapies. Res Clin Dermatol. 2024;7(6):239

Visit for more related articles at Research in Clinical Dermatology

Introduction

Systemic treatments for skin conditions represent a crucial advancement in dermatological care, particularly for patients with severe or widespread conditions that cannot be managed by topical therapies alone. These internal treatments, which are administered orally or via injections, target the body’s internal systems rather than just the surface of the skin. This article will explore the benefits and risks of systemic therapies for skin conditions, highlighting their growing importance in managing complex dermatological diseases [1].

There are several types of systemic therapies used to treat skin conditions. These include oral medications, biologics, immunosuppressants, and systemic corticosteroids. Oral medications such as antibiotics, retinoids, and antifungals are commonly prescribed for conditions like acne, psoriasis, and fungal infections. Biologics, a newer class of drugs, target specific components of the immune system and are particularly effective for autoimmune skin conditions like psoriasis and atopic dermatitis [2].

Systemic treatments work by affecting the underlying mechanisms that contribute to skin disorders. For example, biologics block inflammatory pathways by targeting specific proteins like tumor necrosis factor (TNF) or interleukins, which are involved in the immune response. Immunosuppressants, such as methotrexate, work by suppressing the immune system, reducing inflammation and skin cell turnover in diseases like psoriasis. These treatments are often more effective than topical therapies because they address the root causes of skin conditions rather than just the symptoms [3].

The primary benefit of systemic treatments is their ability to manage severe skin conditions that do not respond to topical medications. For patients with conditions like moderate-to-severe psoriasis or eczema, systemic therapies can significantly reduce symptoms, improve quality of life, and prevent disease progression. Biologics, in particular, have revolutionized treatment for autoimmune skin disorders, offering targeted and effective options with fewer side effects than older systemic treatments [4].

Despite their benefits, systemic treatments come with a range of risks and potential side effects. Common issues include gastrointestinal problems, fatigue, and increased susceptibility to infections. Because many systemic treatments suppress the immune system, patients may be at higher risk for bacterial, viral, or fungal infections. Long-term use of immunosuppressants can also increase the risk of certain cancers, such as lymphoma, which is a major concern for both physicians and patients [5].

Corticosteroids, though highly effective in managing inflammation, come with significant risks when used systemically. Long-term use can lead to side effects like osteoporosis, weight gain, hypertension, and diabetes. For this reason, systemic corticosteroids are often prescribed only for short-term use or in cases where other treatments have failed. Patients on these therapies require close monitoring to manage these potential complications [6].

Biologics have emerged as a game-changing option for patients with severe skin conditions. These drugs are engineered to target specific immune pathways, offering more precise treatment with fewer systemic side effects compared to traditional immunosuppressants. However, biologics are not without risks—they can still cause serious infections, allergic reactions, and may require frequent monitoring to ensure the patient’s safety during treatment [7].

Selecting the appropriate systemic treatment for a skin condition requires a careful assessment of the patient’s medical history, the severity of the disease, and the potential risks associated with each therapy. Physicians must weigh the benefits of controlling the disease against the potential for adverse effects. Often, a combination of therapies, including topical treatments and lifestyle modifications, is recommended to minimize risks while optimizing the treatment’s effectiveness [8].

Ongoing monitoring is essential for patients on systemic therapies. Regular blood tests, imaging, and other evaluations may be necessary to detect potential side effects early. Physicians need to adjust dosages or switch medications if patients experience severe side effects or if the treatment is not effective. Patient education is also crucial in ensuring compliance with therapy and recognizing warning signs of complications [9].

While systemic treatments offer significant benefits for managing chronic skin conditions, their long-term use requires careful planning and monitoring. For many patients, these therapies provide a lifeline, helping them manage conditions that would otherwise cause significant discomfort or disability. However, the potential for long-term risks means that physicians must continuously evaluate the need for ongoing treatment and explore newer, safer options as they become available [10].

Conclusion

Systemic treatments for skin conditions provide substantial benefits for patients with severe or unresponsive diseases. However, the risks associated with these therapies, particularly immunosuppression and long-term side effects, require careful consideration. By choosing the appropriate treatment and closely monitoring patients, physicians can help mitigate these risks while providing relief for those affected by debilitating skin conditions. As research continues to advance, the landscape of systemic therapies will likely evolve, offering new opportunities to improve patient outcomes.

References

  1. Habif TP, Campbell JL, Dinulos JG, et al. Skin disease e-book: Diagnosis and treatment. Elsevier Health Sciences; 2011.

    2. Google Scholar

  2. Hamouzadeh P, Darkhor S, Aboie P, et al. Safety and effectiveness of superficial radiation therapy in the treatment of skin diseases: A systematic review. Health Technology Assessment in Action. 2017.

    3. Indexed at, Google Scholar, Cross Ref

  3. Blume?Peytavi U, Bagot M, Tennstedt D, et al. Dermatology today and tomorrow: From symptom control to targeted therapy. J Eur Acad Dermatol Venereol. 2019;33:3-6.

    4. Indexed at, Google Scholar, Cross Ref

  4. Pope JE, Denton CP, Johnson SR, et al. State-of-the-art evidence in the treatment of systemic sclerosis. Nat Rev Rheumatol. 2023;19(4):212-26.

    5. Indexed at, Google Scholar, Cross Ref

  5. Callen JP, Jorizzo JL, Zone JJ, et al. Dermatological Signs of Systemic Disease E-Book. Elsevier Health Sciences; 2016.

    6. Google Scholar

  6. Modena DA, de Castro Ferreira R, Froes PM, et al. Ozone therapy for dermatological conditions: A systematic review. J Clin Aesthet Dermatol. 2022;15(5):65.

    7. Indexed at, Google Scholar

  7. Lecluse LL, Naldi L, Stern RS, et al. National registries of systemic treatment for psoriasis and the European ‘Psonet’initiative. Dermatol. 2009;218(4):347-56.

    8. Indexed at, Google Scholar, Cross Ref

  8. Bornstein MM, Cionca N, Mombelli A. Systemic conditions and treatments as risks for implant therapy. Int J Oral Maxillofac Implants. 2009;24(Suppl):12-27.

    9. Indexed at, Google Scholar

  9. Gisondi P, Cazzaniga S, Chimenti S, et al. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: Evidence from the Italian Psocare Registry. J Eur Acad Dermatol Venereol. 2013;27(1):e30-41.

    10. Indexed at, Google Scholar, Cross Ref

  10. Richardson SK, Gelfand JM. Update on the natural history and systemic treatment of psoriasis. Adv Dermatology. 2008;24:171.

    11. Indexed at, Google Scholar, Cross Ref

Get the App